Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olomorasib PK study in healthy participants
NCT07794592Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olomorasib in solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Concentration. Started Aug 2026; status: recruiting.
02
Drugs
olomorasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07794592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794592.